Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.
Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.
复制标题
DOI：
10.7150/ijms.13800
复制
发表时间：
2016
影响因子：
3.6
通讯作者：
Sodhi K
中科院分区：
文献类型：
--
作者：
Srikanthan K;Feyh A;Visweshwar H;Shapiro JI;Sodhi K
前言：代谢综合征是一组相关的代谢异常，包括中心性肥胖、高血压、血脂异常、高血糖和胰岛素抵抗，尤其是中心性肥胖和胰岛素抵抗被认为是引起代谢综合征的原因。这些代谢紊乱是心血管疾病的重要危险因素，通常被认为是主要的临床结果，尽管其他结果也是可能的。代谢综合征是一种进行性疾病，包括一系列的疾病，在不同的时间出现特定的代谢异常。这些异常可以通过血清生物标记物进行检测和监测。这篇综述将汇编一个与代谢综合征相关的有前景的生物标记物的清单，这个小组可以帮助在高危人群中及早发现和管理代谢综合征，例如在西弗吉尼亚州。方法：使用PubMed、Science Direct和Google Scholar进行文献综述，搜索与代谢综合征相关的标记物。检索的生物标志物包括脂肪因子(瘦素、脂联素)、神经肽(Ghrelin)、促炎细胞因子(IL-6、肿瘤坏死因子-α)、抗炎细胞因子(IL-10)、抗氧化状态标志物(OxLDL、PON-1、尿酸)和凝血因子(PAI-1)。结果：根据文献报道，代谢综合征患者的促炎性细胞因子(IL-6、肿瘤坏死因子-α)、氧化状态标志物(氧化低密度脂蛋白、尿酸)和凝血因子(PAI-1)水平升高。此外，代谢综合征患者的瘦素浓度也升高，这可能是由于瘦素抵抗所致。相反，在代谢综合征患者中，抗炎细胞因子(IL-10)、Ghrelin、脂联素和抗氧化因子(PON-1)的浓度降低，这些降低也与集群内的特定疾病相关。结论：根据文献中提供的证据，上述生物标志物与代谢综合征显著相关，并可为这些疾病的早期发现和特定治疗提供微创手段。鼓励进行进一步的研究，以确定在临床环境中应用这些生物标志物进行诊断和治疗的有效性。
Introduction: Metabolic syndrome represents a cluster of related metabolic abnormalities, including central obesity, hypertension, dyslipidemia, hyperglycemia, and insulin resistance, with central obesity and insulin resistance in particular recognized as causative factors. These metabolic derangements present significant risk factors for cardiovascular disease, which is commonly recognized as the primary clinical outcome, although other outcomes are possible. Metabolic syndrome is a progressive condition that encompasses a wide array of disorders with specific metabolic abnormalities presenting at different times. These abnormalities can be detected and monitored via serum biomarkers. This review will compile a list of promising biomarkers that are associated with metabolic syndrome and this panel can aid in early detection and management of metabolic syndrome in high risk populations, such as in West Virginia. Methods: A literature review was conducted using PubMed, Science Direct, and Google Scholar to search for markers related to metabolic syndrome. Biomarkers searched included adipokines (leptin, adiponectin), neuropeptides (ghrelin), pro-inflammatory cytokines (IL-6, TNF-α), anti-inflammatory cytokines (IL-10), markers of antioxidant status (OxLDL, PON-1, uric acid), and prothrombic factors (PAI-1). Results: According to the literature, the concentrations of pro-inflammatory cytokines (IL-6, TNF-α), markers of pro-oxidant status (OxLDL, uric acid), and prothrombic factors (PAI-1) were elevated in metabolic syndrome. Additionally, leptin concentrations were found to be elevated in metabolic syndrome as well, likely due to leptin resistance. In contrast, concentrations of anti-inflammatory cytokines (IL-10), ghrelin, adiponectin, and antioxidant factors (PON-1) were decreased in metabolic syndrome, and these decreases also correlated with specific disorders within the cluster. Conclusion: Based on the evidence presented within the literature, the aforementioned biomarkers correlate significantly with metabolic syndrome and could provide a minimally-invasive means for early detection and specific treatment of these disorders. Further research is encouraged to determine the efficacy of applying these biomarkers to diagnosis and treatment in a clinical setting.